Revisiting Richter transformation in the era of novel CLL agents

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F21%3AN0000029" target="_blank" >RIV/00098892:_____/21:N0000029 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/21:73606360

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0268960X21000308" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0268960X21000308</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.blre.2021.100824" target="_blank" >10.1016/j.blre.2021.100824</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Revisiting Richter transformation in the era of novel CLL agents

Popis výsledku v původním jazyce

Richter transformation (RT) is the development of aggressive lymphoma – most frequently diffuse large B-cell lymphoma (DLBCL) and rarely Hodgkin lymphoma (HL) – arising on the background of chronic lymphocytic leukaemia (CLL). Despite recent advances in CLL treatment, RT also develops in patients on novel agents, usually occurring as an early event. RT incidence is lower in CLL patients treated with novel agents in the front line compared to relapsed/refractory cases, with a higher incidence in patients with TP53 disruption. The genetic heterogeneity and complexity are higher in RT-DLBCL than CLL; the genetics of RT-HL are largely unknown. In addition to TP53, aberrations in CDKN2A, MYC, and NOTCH1 are common in RT-DLBCL; however, no distinct RT-specific genetic aberration is recognised yet. RT-DLBCL on ibrutinib is frequently associated with BTK and PLCG2 mutations. Here, we update on genetic analysis, diagnostics and treatment options in RT in the era of novel agents.

Název v anglickém jazyce

Revisiting Richter transformation in the era of novel CLL agents

Popis výsledku anglicky

Richter transformation (RT) is the development of aggressive lymphoma – most frequently diffuse large B-cell lymphoma (DLBCL) and rarely Hodgkin lymphoma (HL) – arising on the background of chronic lymphocytic leukaemia (CLL). Despite recent advances in CLL treatment, RT also develops in patients on novel agents, usually occurring as an early event. RT incidence is lower in CLL patients treated with novel agents in the front line compared to relapsed/refractory cases, with a higher incidence in patients with TP53 disruption. The genetic heterogeneity and complexity are higher in RT-DLBCL than CLL; the genetics of RT-HL are largely unknown. In addition to TP53, aberrations in CDKN2A, MYC, and NOTCH1 are common in RT-DLBCL; however, no distinct RT-specific genetic aberration is recognised yet. RT-DLBCL on ibrutinib is frequently associated with BTK and PLCG2 mutations. Here, we update on genetic analysis, diagnostics and treatment options in RT in the era of novel agents.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood Reviews

ISSN

0268-960X

e-ISSN

1532-1681

Svazek periodika

49

Číslo periodika v rámci svazku

September

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

19

Strana od-do

100824

Kód UT WoS článku

000686765400001

EID výsledku v databázi Scopus

2-s2.0-85103291631